On July 27, 2021, DA32 Life Science Tech Acquisition Corp. announced that Andrew ElBardissi, Keith Crandell, Mara Aspinall, Kevin Hrusovsky, Angela Lai and Nick Roelofs were appointed to the board of directors of the Company (the “Board”). Mr. Hrusovsky, Dr. Roelofs and Mmes. Aspinall and Lai are independent directors. Effective July 27, 2021, Ms. Aspinall, Mr. Hrusovsky and Dr. Roelofs were appointed to the Board’s Audit Committee, with Ms. Aspinall serving as chair of the Audit Committee. Effective July 27, 2021, Dr. Roelofs and Mmes. Aspinall and Lai were appointed to the Board’s Compensation Committee, with Dr. Roelofs serving as chair of the Compensation Committee. The Company does not have a standing Nominating and Corporate Governance Committee, but intends to form one as and when required to do so by law or Nasdaq rules. Mr. Hrusovsky, Dr. Roelofs and Mmes. Aspinall and Lai will participate in the consideration and recommendation of director nominees. Following the appointment of Andrew ElBardissi, Keith Crandell, Mara Aspinall, Kevin Hrusovsky, Angela Lai and Nick Roelofs, the Board is comprised of the following three classes: the term of office of the first class of directors, Class I, consists of Ms. Lai and Dr. Roelofs and will expire at the Company’s first annual meeting of stockholders; the term of office of the second class of directors, Class II, consists of Ms. Aspinall and Mr. Hrusovsky and will expire at the Company’s second annual meeting of stockholders; and the term of office of the third class of directors, Class III, consists of Mr. Crandell and Drs. Kafka and ElBardissi and will expire at the Company’s third annual meeting of stockholders.